Table 1.
Characteristics of the Canadian Fluoroscopy Cohort Study
| Descriptive Characteristics | Value |
|---|---|
| Number of subjects | 63,715 |
| Year of birth, median (range) | 1917 (1853–1949) |
| Females (%) | 49.9 |
| Pulmonary TB (%) | 86.8 |
| Most advanced TB stage recorded, N (%) | |
| minimal | 15,264 (24.0) |
| moderate | 22,696 (35.6) |
| advanced | 16,253 (25.5) |
| Smoking, N (%) | |
| non-smoker | 3,456 (5.4) |
| ever smoker | 10,172 (16.0) |
| not specified | 50,079 (78.6) |
| Number of fluoroscopies,a mean (95% CI)b | 92 (1–360) |
| Duration of fluoroscopies,a years, mean (range) | 2.7 (0.05–35) |
| Cumulative dose to the lungs,c Gy, mean (95% CI)d | |
| from PT | 0.300 (0.140, 0.530) |
| from PP | 0.020 (0.008, 0.037) |
| from AS | 0.007 (0.003, 0.012) |
| from GI series | 0.00007 (0.00001, 0.00023) |
| from all fluoroscopy-guided procedures | 0.320 (0.160, 0.560) |
Abbreviations: AS, aspirations; CI, confidence interval; GI series, gastrointestinal series; Gy, gray; PP, pneumoperitoneum; PT, pneumothorax; SD, standard deviation; TB, tuberculosis.
a
Averaged across all patients in the cohort who received any of the fluoroscopy-guided procedures.
b
2.5th and 97.5th percentiles among patients in the cohort who received the listed procedure.
c
Averaged across all members of the cohort.
d
Mean and 95% CI of estimated cohort average doses from 1,000 alternative realizations using Monte Carlo sampling techniques.